The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma
Source: Pixabay

The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma

The U.S. Food and Drug Administration (FDA) has approved the medicine Keytruda for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, that have relapsed…

Continue Reading The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma